CCL25 and familial pancreatic carcinoma: The CCL25/CCR9 axis reportedly enhances cell proliferation, invasion, and drug resistance via β-catenin activation in pancreatic cancer cells [45], suggesting that β-catenin signaling may also be involved in T-ALL cell migration and invasion.